GUFICBIO Gufic Biosciences Q3 FY25 results (Oct–Dec 2024) and concall
Gufic Biosciences reported a stable Q3 FY25 with slight revenue growth but a dip in profitability margins, primarily due to initial expenses from the newly operational Indore facility. The Indore plant, which started production in October 2024, contributed INR 6 crores in its first quarter and is expected to significantly ramp up, targeting INR 150 crores additional revenue in FY26 and breakeven by Q4 FY26. The company highlighted strong traction in new products like Supergraf and Dalbavancin, while acknowledging price erosion in some critical care molecules and short-term margin pressure.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 |
|---|---|---|
| Revenue | 204 | 208 |
| EBITDA | 39 | 34 |
| Net profit | 22 | 19 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
